macrolide

(redirected from Macrolide antibiotics)
Also found in: Medical, Encyclopedia.

mac·ro·lide

 (măk′rō-līd)
n.
A class of antibiotics that are produced by certain actinomycetes of the genus Streptomyces, are characterized by a large lactone ring linked to one or more sugars, and act by inhibiting protein synthesis.

[German Makrolid : makro-, macro- + L(acton), lactone + -id, -ide.]

macrolide

(ˈmækrəˌlaɪd)
n
any of a class of antibiotic drugs derived from streptomycetes
References in periodicals archive ?
The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland.
Of these 31 children, 21 (68%) had already been treated with 14- or 15-membered macrolide antibiotics before admission.
Macrolide antibiotics are not only active against Gram-positive bacteria but also against some other organism like Haemophilus influenza, Mycoplasma spp.
In the June 2013 issue of DukeMedicine HealthNews, we discussed the increased risk of arrhythmias, heart attacks and death from cardiovascular events from macrolide antibiotics used to treat respiratory infections.
Macrolide antibiotics have anti-inflammatory properties and there is evidence from cell studies in the laboratory that they can boost anti-viral immunity.
Among patients, 92 (79%) were treated with macrolide antibiotics.
Macrolide antibiotics such as azithromycin have immunomodulatory and anti-inflammatory properties in addition to their antibacterial action.
Recombineering reveals a diverse collection of ribosomal proteins L4 and L22 that confer resistance to macrolide antibiotics.
Macrolide antibiotics have antimicrobial and immunomodulary effects, and chronic administration has been associated with improvements in other Inflamtnatory lung conditions, such as cystic fibrosis.
The well-documented benefits far outweigh the uncertain risks associated with pneumococcal resistance to macrolide antibiotics.
The two posters compared the anti-inflammatory activity of CEM-101 to several available macrolide antibiotics in an in vitro inflammation model for chronic obstructive pulmonary disease (COPD).
The Company is the largest domestic manufacturer of macrolide antibiotics, with a leading position for its intravenous infusion solution products in high-end hospital market.